Deep vein thrombosis (DVT) often brings with it the risk of post-thrombotic syndrome (PTS), an under-recognized but serious complication that often causes long-term disability for patients. During March s DVT Awareness Month, the Society of Interventional Radiology wants to help patients and family members to better understand the long-term risks of DVT.
First Ten Patients Enrolled in U.S. Clinical Study that is Evaluating Treatment of Iliofemoral Venous Outflow Obstruction
A study that set out to assess the safety and efficacy of prostate artery embolization in small volume benign prostatic hyperplasia (<50cc) revealed that the procedure appears to offer positive clinical benefits for patients out to six months.
Men with benign prostatic hyperplasia can get relief from symptoms such as frequent night urination with prostatic artery embolization, suggests long-term research presented at the 26th annual International Symposium on Endovascular Therapy (ISET, 18–22 January, Miami, USA).
Following on from the news that Medtronic’s SYMPLICITY HTN-3 study failed to meets its primary efficacy endpoint, Covidien has announced it will exit its OneShot renal denervation programme. The company states that this "voluntary action" is primarily in response to a slower than expected development of the renal denervation market and that the decision resulted from Covidien’s regular review of strategic programmes and growth potential for various aspects of its product portfolio.
In the interventional world, technologies rapidly oscillate between being the high of the “next big thing” and then the low of being “killed off” with the publication of negative trials. Medtronic recently announced that its sham-controlled renal denervation study, SYMPLICITY HTN-3, failed to meet its primary efficacy. Now, Covidien has announced that it is "exiting" the OneShot Renal Denervation Program. Interventional News learns from leaders in the field that the watchword is: “wait for the publication”. “A critical analysis of the full dataset and study design are now imperative before the interventional community leaps to any conclusions about whether renal denervation works or not to control true resistant hypertension,” they say.
EKOS Corporation announced on 20 January 2014 the publication of the results of its ULTIMA (Ultrasound accelerated thrombolysis of pulmonary embolism) trial in Circulation. The announcement was made at the International Symposium on Endovascular Therapy (ISET) in Miami, USA.
Investigators from the MORE (Metastatic colorectal cancer liver metastases outcomes after radioembolization) study have released new findings at the American Society of Clinical Oncology’s 2014 Gastrointestinal Cancers Symposium confirming that standard laboratory tests are a valuable tool for predicting patient outcomes prior to Selective Internal Radiation Therapy (SIRT).
Cryoablation kills tumours and provides pain relief to patients whose cancer has spread to the bone and soft tissue, suggests research being presented at the 6th annual Symposium on Clinical Interventional Oncology (CIO), in collaboration with the International Symposium on Endovascular Therapy (ISET).
Vascular Solutions has announced the US market launch of Thrombidisc topical haemostat, a thrombin-based pad used as an adjunct to manual compression to control surface bleeding from vascular access sites and percutaneous catheters or tubes.
Benvenue Medical has received FDA 510(k) clearance for its Kiva system for the reduction and treatment of vertebral compression fractures. The system is a novel implant-based solution for vertebral augmentation and a departure from balloon kyphoplasty and, therefore, it is the first new approach to the treatment of vertebral compression fractures in over a decade.
ReCor Medical has announced that it has received CE-mark approval for the latest generation of its ultrasound-based renal denervation system (Paradise). It adds that the first patients were treated with the new system in December 2013 at the Universitäts–Herzzentrum, Bad Krozingen, Germany; the company also announced the first use of its new catheter line, called Radiance, which is 5 French and rapid-exchange compatible, and thus sized to be introduced via the radial artery (as opposed to the femoral artery).
Sapheon has announced that it has submitted the second module of the pre-market approval (PMA) application for the VenaSeal Sapheon Closure System to the US Food and Drug Administration (FDA). According to the company, the submission, which was completed on 18 December 2013, “represents steady progress on the modular PMA application for VenaSeal, a minimally invasive, single use kit intended for the treatment of venous reflux disease”. The first module, submitted in September 2013, was reviewed by the FDA and accepted without deficiencies within a single review cycle.
Argon Medical Devices announced that it has received clearance from the US Food and Drug Administration to begin marketing the Option Elite retrievable inferior vena cava filter with a new over-the-wire delivery technique on 16 January 2013.
CVRx has announced that findings from a health-economic analysis, published in the Journal of Hypertension, indicate Barostim therapy is a cost-effective treatment option for patients with drug-resistant hypertension. The Barostim system is a programmable, minimally invasive device that consists of an implantable pulse generator (IPG), a 2mm electrode, and an external programmer.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos